



 **TOFIGH DARU**  
توفیق دارو

**TOFIGH DARU**

*Research & Engineering Company*



Established in 2000 as a research based company, Tofigh Daru has been involved in development & production of diverse range of APIs for finished dosage forms.

Our Expertise include –

- High Potent & LVHV APIs
- Chemical Synthesis
- Pharmaceutical Peptides
- Biologic Research
- Novel Drug Delivery Systems
- Formulation & Regulatory Support





48 registered APIs manufactured in the following categories through 6 GMP approved production lines –

- High Potent OEB 4 & 5
- Narcotics
- Low Volume High Value (LVHV)
- Peptides
- Glatiramer

## Services Offered –

- Analytical
  - Method Development for non standard RM, FG
  - Method Validation as per ICH
  - Analytical Testing of RM & FG
  - Microbial Analysis
- Formulation Development & Tech Transfers
- Engineering Support
  - Conceptual, Basic & Detailed



## Immunomodulatory Agents

No	Products	Application	CAS No.	Method of analysis
1	<i>Fingolimod HCl</i>	Multiple Sclerosis	162359-56-0	<i>Method of analysis</i>
2	<i>Glatiramer Acetate</i>	Multiple Sclerosis	147245-92-9	<i>USP 43</i>
3	<i>Teriflunomide</i>	Multiple Sclerosis	163451-81-8	<i>In House</i>
4	<i>Dimethyl Fumarate</i>	Multiple Sclerosis	624-49-7	<i>In House</i>
5	<i>Diroximel Fumarate</i>	Multiple Sclerosis	1577222-14-0	<i>In House</i>
6	<i>Siponimod Fumaric Acid</i>	Multiple Sclerosis	1230487-00-9	<i>In House</i>

## Endocrine System

No	Products	Application	CAS No.	Method of analysis
1	<i>Sitagliptin Phosphate Monohydrate</i>	<i>Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor</i>	<i>654671-77-9</i>	<i>USP 43</i>
2	<i>Empagliflozin</i>	<i>Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor</i>	<i>864070-44-0</i>	<i>In House</i>
3	<i>Dapagliflozin Propandiol</i>	<i>Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor</i>	<i>461432-26-8</i>	<i>In House</i>

## Cardiovascular

No	Products	Application	CAS No.	Method of analysis
1	<i>Rivaroxaban</i>	<i>Factor Xa Inhibitors /Anti-coagulant</i>	366789-02-8	<i>In House</i>
2	<i>Apixaban</i>	<i>Factor Xa Inhibitors /Anti-coagulant</i>	503612-47-3	<i>In House</i>

## Narcotic

No	Products	Application	CAS No.	Method of analysis
1	<i>Fentanyl Citrate (BP/USP)</i>	<i>Anesthesia, Analgesia</i>	<i>990-73-8</i>	<i>USP 43/BP2022</i>
2	<i>Remifentanyl HCl</i>	<i>Anesthesia, Analgesia</i>	<i>132539-07-2</i>	<i>In House</i>
3	<i>Sufentanyl Citrate</i>	<i>Anesthesia, Analgesia</i>	<i>60561-17-3</i>	<i>BP2022</i>
4	<i>Alfentanyl HCl</i>	<i>Anesthesia, Analgesia</i>	<i>69049-06-5</i>	<i>In House</i>



## Peptide

No	Products	Application	CAS No.	Method of analysis
1	<i>Alarelin Acetate</i>	<i>Induction of Ovulation Fertilization in Animals</i>	79561-22-1	<i>In House</i>
2	<i>Buserelin Acetate</i>	<i>Advanced Prostate &amp; Breast Cancer Infertility, Endometriosis</i>	68630-75-1	<i>BP 2022</i>
3	<i>Octreotide Acetate</i>	<i>Acromegaly Carcinoid Tumors</i>	79517-01-4	<i>USP 43</i>
4	<i>Triptoreline Acetate</i>	<i>Prostate &amp; Breast Cancer, Endometriosis, Precocious Puberty</i>	140194-24-7	<i>In House</i>
5	<i>Cetrorelix Acetate</i>	<i>Use in IVF, Advanced Prostate Cancer, Infertility, Endometriosis</i>	145672-81-7	<i>In House</i>
6	<i>Carfilzomib</i>	<i>Multiple Myeloma</i>	868540-17-4	<i>In House</i>

## Miscellaneous

No	Products	Application	CAS No.	Method of analysis
1	<i>Atracurium Besylate</i>	<i>Anesthesia(Neuromuscular Blocking)</i>	64228-81-5	USP 43
2	<i>Aprepitant</i>	<i>Prevention of chemotherapy-induced nausea and vomiting</i>	170729-80-3	USP 43

## Anticancer

No	Products	Application	CAS No.	Method of analysis
1	<b>Bortezomib</b>	<i>Multiple Myeloma</i>	179324-69-7	<i>In House</i>
2	<b>Zoledronic Acid Monohydrate</b>	<i>Preventing Skeletal Fractures in Cancers in Patients For Treating Osteoporosis</i>	165800-06-6	<i>In House</i>
3	<b>Letrozole</b>	<i>Breast Cancer (Post-menopausal Estrogen-receptor-positive)</i>	112809-51-5	<i>USP 43</i>
4	<b>Dasatinib Monhydrate</b>	<i>Chronic Myelogenous Leukemia (CML)</i>	863127-77-9	<i>In House</i>
5	<b>Sunitinib Malate</b>	<i>Renal Cell Carcinoma GIT Tumors</i>	341031-54-7	<i>In House</i>
6	<b>Nilotinib HCl Monohydrate</b>	<i>Chronic Myelogenous Leukemia (CML)</i>	923288-90-8	<i>In House</i>
7	<b>Pomalidomide</b>	<i>Multiple Myeloma</i>	19171-19-8	<i>In House</i>
8	<b>Enzalutamide</b>	<i>Androgen receptor inhibitor Castration-resistant prostate cancer</i>	915087-33-1	<i>In House</i>
9	<b>Lenalidomide Hemihydrate</b>	<i>Multiple Myeloma</i>	191732-72-6	<i>In House</i>
10	<b>Thalidomide</b>	<i>Multiple Myeloma</i>	50-35-1	<i>USP 42</i>
11	<b>Temozolomide</b>	<i>Brain tumors such as glioblastoma multiform or anaplastic astrocytoma</i>	85622-93-1	<i>USP 43</i>
12	<b>Docetaxel Trihydrate</b>	<i>Breast Cancer, Non-Small Cell, Lung Cancer, Andero-carcinoma</i>	114977-28-5	<i>In House</i>
13	<b>Ixazomib Citrate</b>	<i>Multiple Myeloma</i>	1072833-77-2	<i>In House</i>
14	<b>Ibrutinib</b>	<i>Chronic Lymphocytic Leukemia (CLL)</i>	936563-96-1	<i>In House</i>

## Antiviral Agents

No	Products	Application	CAS No.	Method of analysis
1	<i>Molnupiravir</i>	<i>Antiviral/Influenza/ Covid-19</i>	2349386-89-4	<i>In House</i>
2	<i>Remdesivir</i>	<i>Broad-spectrum antiviral agent Covid-19</i>	1809249-37-3	<i>In House</i>
3	<i>Umifenovir</i>	<i>Antiviral/Influenza/ Covid-19</i>	868364-57-2	<i>In House</i>
4	<i>Oseltamivir Phosphate</i>	<i>Antiviral/Influenza A &amp; B</i>	204255-11-8	<i>USP 43</i>